You are here

Gene Therapy Fast-Tracked for Huntington’s Disease Treatment

First Patient Expected to Receive AMT-130 Therapy in 2019

uniQure N.V. has received a fast track designation from the FDA for AMT-130, a gene therapy candidate for the treatment of Huntington’s disease. The agent comprises a recombinant AAV5 vector with a DNA cassette encoding a microRNA that non-selectively reduces human huntingtin protein in patients with Huntington’s disease. AMT-130 is unique as it targets the highly toxic exon1 protein fragment, which is more toxic than the mutant huntingtin protein. 

Huntington’s disease affects an estimated three to seven per 100,000 people of European ancestry. Adult-onset Huntington’s disease, the most common form, usually appears during the ages of 30 to 40 years. The rarer juvenile form begins in childhood or adolescence, and typically progresses at a faster rate than the adult-onset form. Affected individuals usually live 10 to 15 years after signs and symptoms appear. There are no approved therapies to delay the onset or slow the progression of the disease.

uniQure is poised to begin the phase 1/2 study of AMT-130, which is the first, one-time administered adeno-associated viral gene therapy to enter clinical testing for Huntington’s disease. The company is on track to treat the first patient in the second half of 2019.

Source: uniQure N.V., April 8, 2019

Recent Headlines

Specific Monoclonal Antibodies Ensure Extreme Sensitivity, Accuracy
Record-High Number of Cases in France, Italy, Greece, Other Locations
Will Have a Longer Shelf Life Than Current, Expired Stockpile
Most Women Undergoing Surgery for Suspected Cancer Do Not Have It
Almost 64% of Patients Showed Decreased Hemoglobin A1c Levels
Lifesaving Life Foam for Battlefield, Terrorist Attacks, Trauma
Cell Reprogramming Process May Benefit Patients Prone to Severe Hypoglycemia
Beagles Beat Out Advanced Technology